|Bid||98.52 x 100|
|Ask||98.55 x 200|
|Day's Range||98.14 - 98.60|
|52 Week Range||67.04 - 104.78|
|PE Ratio (TTM)||49.54|
|Forward Dividend & Yield||1.40 (1.43%)|
|1y Target Est||N/A|
ResMed (RMD) consistently invests and expands globally in high-growth markets like China, South Korea, India, Brazil and across the Eastern Europe belt.
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
LabCorp's (LH) Covance Drug Development of late begins to gain traction from Chiltern acquisition, strong organic growth and a favorable foreign currency translation.
We are encouraged by Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific.
Integra LifeSciences (IART) witnesses strong global sales within specialty surgical driven by strength in door repair and tissue ablation franchises in Asia Pacific and Europe.
Thermo Fisher (TMO) registers a solid international performance in Q4 with strong year-over-year growth in the Asia-Pacific and the emerging markets of China, South Korea and the Middle East.
ResMed's (RMD) product launches and strategies to gain traction in the sleep-disordered breathing market. This upside is further likely to drive the stock in the future.
Keith Bliss of Cuttone and Company joins Yahoo Finance's Melody Hahm from the floor of the New York Stock Exchange to discuss the latest in the markets.